Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
PainVirtual RealityPlaceboTemporomandibular Disorder
Interventions
BEHAVIORAL

Active Virtual Reality

Participants will be assigned to an immersive VR environment.

BEHAVIORAL

sham Virtual Reality

Participants will be assigned to a sham VR environment without the immersive experience.

OTHER

No Intervention

Participants will experience tonic pain tolerance tests without exposure to any environments.

DRUG

Naloxone

"4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."

OTHER

Saline

"Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."

OTHER

Natural history

Participants will not be provided Naloxone or Saline.

Trial Locations (1)

21201-1512

RECRUITING

Luana Colloca, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER